²²⁵Ac-Radiopharmaceutical

The ²²⁵Ac-radiopharmaceutical is a targeted drug utilizing the radioisotope ²²⁵Ac, widely applied in targeted cancer therapies, with notable potential in radioimmunotherapy. Alfa Cytology is passionately dedicated to developing this groundbreaking radiopharmaceutical, integrating advanced radiation pharmacology technologies to offer innovative cancer treatment solutions and actively support its expanded preclinical application across diverse cancer types and potential therapeutic avenues.

Introduction to ²²⁵Ac-Radiopharmaceutical

²²⁵Ac-radiopharmaceuticals are targeted drugs using the radioisotope actinium-225 (²²⁵Ac). With a long half-life and potent radioactive decay, ²²⁵Ac emits alpha particles, showing promise in treating certain cancers, particularly in radioimmunotherapy. The high energy of alpha particles destroys tumor cells while minimizing damage to healthy tissues, offering high therapeutic specificity. ²²⁵Ac-radiopharmaceuticals deliver radioactivity directly to cancer cells by binding to targeting molecules, like antibodies, peptides, or small molecules, thereby enhancing therapeutic outcomes.

Fig.1 Bioconjugation of YS5 with Macropa-NCS and Macropa-PEG_4/8-TFP ester followed by radiolabeling with ²²⁵Ac(NO₃)₃. (BOBBA K N, et al., 2024)

Advantages of ²²⁵Ac-Radiopharmaceutical

• Efficient Alpha Particle Radiation

Mechanism: ²²⁵Ac decays into substrates, emitting α particles that penetrate only a few micrometers but deliver high energy, causing significant cellular damage within a short range.

Precision Targeting: The high-energy, short-range attributes of alpha particles make them ideal for accurately targeting and eradicating cancer cells.

• Strong Targeting with Reduced Side Effects

Targeted Delivery: ²²⁵Ac can be conjugated with monoclonal antibodies, ADCs, or other targeting molecules to deliver radioactivity directly to tumors.

Effectiveness in Small Lesions: Its potent energy effectively treats small metastatic lesions and difficult tumors.

Reduced Collateral Damage: α particles from ²²⁵Ac limit damage to adjacent healthy tissue, offering localized destruction superior to β particles and γ rays.

• Multiple Decay Chain Effects

Radionuclide Production: ²²⁵Ac generates radionuclides like ²¹³Bi, emitting α or β particles and enhancing radiation effects.

Enhanced Therapy: These combined effects improve the eradication of resistant cancer cells.

• Wide Therapeutic Range

Cancer Versatility: Applicable to diverse cancers, including lymphomas, leukemias, and solid tumors like prostate cancer.

Combinable Treatment: ²²⁵Ac enhances outcomes when paired with chemotherapy, immunotherapy, or targeted drugs, reducing resistance.

Our Services

Alfa Cytology is passionately committed to the comprehensive research and development of ²²⁵Ac-radiopharmaceuticals, exploring their groundbreaking applications in targeted radiotherapy. By specializing in crafting highly effective and safe therapeutic solutions, we aim to drive significant innovation and progress in the evolving field of nuclear medicine, ultimately improving patient outcomes and transforming cancer treatment.

Imaging Services for ²²⁵Ac-Radiopharmaceutical

Alfa Cytology offers ²²⁵Ac radiopharmaceutical imaging services, utilizing the alpha-radiation properties of ²²⁵Ac to achieve high-precision molecular imaging, which is crucial for the evaluation and monitoring of targeted tumor therapies.

With robust research and development capabilities and a cutting-edge R&D platform, Alfa Cytology is committed to advancing the development and application of ²²⁵Ac radiopharmaceuticals. By fostering collaborations with leading scientific institutions and industry experts, we aim to accelerate progress. For any inquiries or further information, please don't hesitate to contact us. We are dedicated to providing comprehensive solutions tailored to your needs through our seamless, one-stop service.

Reference

1. BOBBA K N, BIDKAR A P, WADHWA A, et al. Development of CD46 targeted alpha theranostics in prostate cancer using (¹³⁴)Ce/(²²⁵)Ac-Macropa-PEG(₄)-YS5 [J]. Theranostics, 2024, 14(4): 1344-60.

• ⁶⁸Ga-Radiopharmaceutical
• ¹⁸F-Radiopharmaceutical
• ⁸⁹Zr-Radiopharmaceutical
• ⁹⁹mTc-Radiopharmaceutical
• ¹²³I-Radiopharmaceutical
• ¹²⁵I-Radiopharmaceutical
• ¹³¹I-Radiopharmaceutical
• ¹¹C-Radiopharmaceutical
• ¹⁴C-Radiopharmaceutical
• ¹⁷⁷Lu-Radiopharmaceutical
• ⁹⁰Y-Radiopharmaceutical
• ⁸⁹Sr-Radiopharmaceutical